TETRAPHASE PHARMACEUTICALS I's ticker is TTPHXXXX and the CUSIP is 88165N105. A total of 79 filers reported holding TETRAPHASE PHARMACEUTICALS I in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $55,000 | -70.6% | 40,829 | -75.3% | 0.00% | – |
| Q4 2018 | $187,000 | -48.2% | 165,525 | +26.7% | 0.00% | – |
| Q3 2018 | $361,000 | -28.5% | 130,633 | -7.6% | 0.00% | – |
| Q2 2018 | $505,000 | +42.3% | 141,453 | +22.2% | 0.00% | – |
| Q1 2018 | $355,000 | -33.5% | 115,798 | +36.6% | 0.00% | -100.0% |
| Q4 2017 | $534,000 | +15.3% | 84,741 | +25.3% | 0.00% | 0.0% |
| Q3 2017 | $463,000 | -6.7% | 67,628 | -2.8% | 0.00% | 0.0% |
| Q2 2017 | $496,000 | -13.6% | 69,595 | +11.5% | 0.00% | 0.0% |
| Q1 2017 | $574,000 | +180.0% | 62,423 | +22.5% | 0.00% | – |
| Q4 2016 | $205,000 | +10.2% | 50,965 | +4.7% | 0.00% | – |
| Q3 2016 | $186,000 | +45.3% | 48,656 | +63.1% | 0.00% | – |
| Q2 2016 | $128,000 | +60.0% | 29,841 | +178.9% | 0.00% | – |
| Q3 2015 | $80,000 | -91.0% | 10,699 | -42.8% | 0.00% | -100.0% |
| Q2 2015 | $887,000 | +63.7% | 18,694 | +26.4% | 0.00% | +100.0% |
| Q1 2015 | $542,000 | -5.1% | 14,792 | +2.9% | 0.00% | 0.0% |
| Q4 2014 | $571,000 | – | 14,375 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 1,048,642 | $3,219,000 | 0.50% |
| Virtus ETF Advisers LLC | 130,920 | $402,000 | 0.35% |
| 683 Capital Management, LLC | 600,000 | $1,842,000 | 0.16% |
| Tekla Capital Management LLC | 859,322 | $2,638,000 | 0.10% |
| DOW CHEMICAL CO /DE/ | 65,000 | $200,000 | 0.07% |
| Alambic Investment Management, L.P. | 115,834 | $356,000 | 0.05% |
| A.R.T. Advisors, LLC | 262,896 | $807,000 | 0.03% |
| Candriam S.C.A. | 520,613 | $1,598,000 | 0.03% |
| Man Group plc | 1,674,341 | $5,140,000 | 0.02% |
| Baker Brothers Advisors | 935,000 | $2,870,000 | 0.02% |